New Study Links Obesity to Faster Alzheimer’s Progression
A recent study from Washington University Medicine in St. Louis, Missouri, has found a worrying connection between obesity and Alzheimer’s disease. The research shows that people with obesity experience a significant increase in Alzheimer’s-related blood markers, escalating 95% faster than those without obesity.
Presented at the annual meeting of the Radiological Society of North America in Chicago, the study analyzed data from 407 participants over five years, focusing on PET scans and blood samples from the Alzheimer’s Disease Neuroimaging Initiative.
Initially, researchers noted that individuals with higher body mass index (BMI) had lower Alzheimer’s blood markers. This was likely due to a larger blood volume in heavier individuals, which diluted the biomarkers. However, as time went on, those with obesity exhibited a higher burden of Alzheimer’s disease compared to their non-obese counterparts.
The study also found a direct relationship between Alzheimer’s biomarkers and brain imaging results, highlighting an accumulation of amyloid plaques—key indicators of Alzheimer’s disease.
Dr. Soheil Mohammadi, the lead author of the study, emphasized the findings, stating, “Our study demonstrates that obesity is linked to a steady increase in Alzheimer’s-related issues over five years.” He highlighted how sensitive blood biomarkers can detect changes more effectively than brain imaging.
Dr. Cyrus Raji, a senior author, pointed out that overall body health, including conditions like obesity, plays a significant role in the progression of Alzheimer’s. “It is critical to take care of your body to support brain health,” he said.
Recent clinical trials have looked into whether medications aimed at reducing body weight, such as semaglutide (Ozempic), can help slow cognitive decline in early Alzheimer’s patients. While some trials have not shown positive results, the researchers hope that their findings motivate future studies on treating obesity earlier in life to possibly prevent Alzheimer’s.
Notably, not all types of body fat pose the same risks for Alzheimer’s. Dr. Mohammadi indicated that future research should explore the differences in how various fat types affect brain health.
Dr. Marc Siegel, a senior medical analyst who did not participate in the study, called the findings significant. “Obesity is linked to inflammation and insulin resistance, which can trigger neuroinflammation—one of the key drivers of Alzheimer’s,” he explained.
The study does come with limitations, including its relatively small sample size and the use of observational data, which can point out connections but does not establish direct causation. Other factors associated with obesity, like diabetes and high blood pressure, might also influence changes in Alzheimer’s biomarkers.
Overall, this research highlights the urgent need for larger-scale studies with diverse participants to further investigate the relationship between obesity and Alzheimer’s disease progression.
